Diabetes

  • A person eats oatmeal with berries, and a phone on the counter shows their current glucose levels.
    Image attribution tooltip
    Courtesy of Abbott
    Image attribution tooltip

    Who benefits from over-the-counter CGMs?

    Experts speaking at the ADA’s Scientific Sessions supported making CGMs more accessible, but debated their usefulness for adults without diabetes.

    By • July 1, 2025
  • A person sits on a couch with a white patch on their upper arm and a rectangular device with a screen on their hip.
    Image attribution tooltip
    Courtesy of Beta Bionics
    Image attribution tooltip

    New glucose sensors, insulin patch pumps lead ADA’s Scientific Sessions

    The diabetes conference featured a debate about over-the-counter glucose monitors and updates on upcoming devices, including insulin patch pumps. Here’s a roundup of MedTech Dive’s coverage.

    By • July 1, 2025
  • Professional photo of Elizabeth Gasser
    Image attribution tooltip
    Permission granted by Tandem Diabetes Care
    Image attribution tooltip

    Tandem’s Elizabeth Gasser on patch pump plans, Abbott partnership

    The strategy and product exec said Tandem aims to give patients options and reach more people who haven’t yet used insulin pumps.

    By • June 25, 2025
  • A person holds a phone, wearing a white patch on their forearm and an insulin pump on their hip.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors

    Medtronic, Beta Bionics and Tandem Diabetes Care showcased planned patch pumps at the conference, while Senseonics shared updates on its implantable glucose sensors.

    By • June 24, 2025
  • Professional photo of Eric Benjamin
    Image attribution tooltip
    Permission granted by Insulet
    Image attribution tooltip

    Insulet’s Eric Benjamin shares update on automated insulin delivery system

    The chief product and customer experience officer said Insulet has seen an uptick in users with Type 2 diabetes since receiving an expanded indication, and shared an update on plans for a closed-loop system.

    By • June 23, 2025
  • A view of the Chicago skyline.
    Image attribution tooltip
    JMSilva via Getty Images
    Image attribution tooltip

    5 things to watch at the ADA’s Scientific Sessions

    The American Diabetes Association’s annual conference kicks off amid a dynamic year for diabetes tech, as access improves for people with Type 2 diabetes and companies debut new devices.

    By • June 20, 2025
  • A black, rectangular device displays a blood glucose reading, while a white patch that says Dexcom One+ is to the right.
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom recalls more than 700,000 CGM receivers for lack of audible alarm

    Severe adverse events, including seizure and loss of consciousness, were potentially linked to the issue, based on 56 reports Dexcom received.

    By • Updated June 24, 2025
  • Chris smiles and wears a brown jacket.
    Image attribution tooltip
    Permission granted by Abbott
    Image attribution tooltip
    Q&A

    Abbott’s new diabetes leader on latest sensors, partnerships and Type 2 coverage

    Ahead of the American Diabetes Association’s Scientific Sessions, Chris Scoggins said Abbott’s ambition is to be the most broadly connected diabetes tech company.

    By • June 12, 2025
  • A person walks in a forest with a square device taped to their thigh.
    Image attribution tooltip
    Courtesy of Tandem Diabetes Care
    Image attribution tooltip

    Tandem, Abbott team on insulin delivery with glucose-ketone sensor

    Tandem will integrate its insulin delivery systems with a new dual glucose-ketone sensor being developed by Abbott.

    By • June 10, 2025
  • A closeup of an entryway that reads the Federal Trade Commission.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Owens & Minor spikes $1.36B Rotech buyout over regulatory barriers

    The companies scrapped the merger because securing FTC clearance “proved unviable in terms of time, expense and opportunity.”

    By • June 6, 2025
  • A group of people cheering inside the Nasdaq building, standing behind a podium.
    Image attribution tooltip
    Permission granted by Beta Bionics
    Image attribution tooltip
    Q&A

    Beta Bionics CEO, CFO on how to take a company public

    CEO Sean Saint and CFO Stephen Feider spoke about what’s different now that the company is public and the long journey of pursuing an IPO.

    By • June 2, 2025
  • A person looks at a smartwatch while walking past packaged produce.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Why Medtronic plans to spin out its diabetes business

    While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on segments with higher margins.

    By • May 22, 2025
  • The exterior of Medtronic's Minnesota operational headquarters is shown along with its reflection in a pool of water.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic plans to spin off diabetes business within 18 months

    CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech competitor.

    By • May 21, 2025
  • Professional photo of Kevin Sayer
    Image attribution tooltip
    Permission granted by Dexcom
    Image attribution tooltip

    Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products

    In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.

    By • May 16, 2025
  • Professional photo of Dev Kurdikar
    Image attribution tooltip
    Permission granted by Embecta
    Image attribution tooltip

    Embecta restructures again, outlines tariff costs

    The diabetes tech company announced a second restructuring after ending its insulin patch-pump program.

    By • May 13, 2025
  • An exterior photo of a corporate campus shows flat buildings and a grassy lawn.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche plans $550M expansion of Indianapolis site to manufacture CGMs

    Roche Diagnostics plans to produce glucose monitors at the site within three years and prepare for future generations of its sensors.

    By • May 12, 2025
  • Professional photo of Ashley McEvoy
    Image attribution tooltip
    Permission granted by Insulet
    Image attribution tooltip

    New Insulet CEO Ashley McEvoy sets priorities

    The diabetes tech company raised its expectations for revenue and gross margins, despite the impact of tariffs.

    By • May 9, 2025
  • Professional photo of Osagie Ebekozien
    Image attribution tooltip
    Permission granted by The American Diabetes Association
    Image attribution tooltip
    Q&A

    ADA’s Osagie Ebekozien on diabetes tech for Type 2, new CGM standards

    Ebekozien, chief quality officer of the American Diabetes Association, said the nonprofit is seeing a shift with more devices authorized for Type 2 diabetes.

    By • May 9, 2025
  • Epic's logo on top of its booth at HIMSS23.
    Image attribution tooltip
    Rebecca Pifer/MedTech Dive
    Image attribution tooltip

    Abbott integrates diabetes data into Epic’s electronic health records

    Linking the systems will allow clinicians to view glucose data captured by Libre glucose sensors within Epic’s systems.

    By • May 1, 2025
  • A black reader is shown on top of a phone with a blood glucose reading.
    Image attribution tooltip
    Permission granted by Senseonics
    Image attribution tooltip

    Senseonics, Sequel partner to use 1-year CGM in automated insulin dosing system

    The partnership extends the compatibility of Sequel’s Twiist system to allow people with Type 1 diabetes to pair the device with Senseonics’ Eversense 365 CGM.

    By • April 30, 2025
  • Professional photo of Ashley McEvoy
    Image attribution tooltip
    Permission granted by Insulet
    Image attribution tooltip

    Ashley McEvoy named Insulet CEO

    McEvoy, the former leader of Johnson & Johnson’s medtech business, started immediately. Jim Hollingshead, who was CEO of Insulet for three years, resigned on Monday but will work as a consultant.

    By • April 28, 2025
  • A person stands outside wearing a small, square device with a cord on their belt.
    Image attribution tooltip
    Permission granted by Medtronic
    Image attribution tooltip

    Medtronic seeks FDA nod for insulin pump, furthering Abbott collab

    Receiving FDA clearance would allow Medtronic to pair its pumps with a glucose monitor being developed for the company by Abbott.

    By • April 24, 2025
  • A person holds a phone, wearing a white patch on their forearm and an insulin pump on their hip.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic gets FDA approval to use Simplera Sync glucose sensor with insulin pumps

    The updated device allows users to pair the sensor with Medtronic’s insulin pumps, and is expected to grow the company’s diabetes business.

    By • April 21, 2025
  • The entrance to Illumina's San Diego campus.
    Image attribution tooltip
    Courtesy of Illumina
    Image attribution tooltip

    Illumina, Tempus AI partner to drive genomic testing beyond cancer

    The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.

    By • April 18, 2025
  • A person smiles and holds a spoon. A white patch is on their right upper arm.
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom nets FDA clearance for 15-day CGM

    The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.

    By • April 10, 2025